Antagonists of HMG1 for treating inflammatory conditions
View Patent ↗There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
1. A method for diagnosing a condition characterized by activation of the inflammatory cytokine cascade in a mammalian subject, comprising measuring the concentration of HMG1 in a test sample from the subject, and comparing that concentration to a standard for HMG1 representative of a normal range of HMG1 in a like sample, wherein a level of HMG1 in the test sample higher than the standard indicates a diagnosis of a condition characterized by activation of the inflammatory cytokine cascade.
2. The method of claim 1 , wherein the condition is arthritis.
3. The method of claim 1 , wherein the condition is systemic lupus erythematosis.
4. The method of claim 1 , wherein the sample is a blood or serum sample.
5. The method of claim 1 , wherein the mammalian subject is human.
6. The method of claim 1 , wherein the concentration of HMG1 is measured using an antibody that binds an HMG1 protein.
7. A prognostic method for monitoring the severity and predicting the likely clinical course of a mammalian subject having a condition characterized by activation of the inflammatory cytokine cascade, comprising measuring the concentration of HMG1 in a test sample from the subject, and comparing that concentration to a standard for HMG1 representative of a normal range of HMG1 in a like sample, wherein the magnitude of the difference between the level of HMG1 in the test sample and the standard positively correlates with the severity of the condition characterized by activation of the inflammatory cytokine cascade and with a poor prognosis of the condition.
8. The method of claim 7 , wherein the condition is arthritis.
9. The method of claim 7 , wherein the condition is systemic lupus erythematosis.
10. The method of claim 7 , wherein the sample is a blood or serum sample.
11. The method of claim 7 , wherein the mammalian subject is human.
12. The method of claim 7 , wherein the concentration of HMG1 is measured using an antibody that binds an HMG1 protein.
13. A method for diagnosing rheumatoid arthritis in a mammalian subject, comprising measuring the concentration of HMG1 in a test sample from the subject, and comparing that concentration to a standard for HMG1 representative of a normal range of HMG1 in a like sample, wherein a level of HMG1 in the test sample higher than the standard indicates a diagnosis of rheumatoid arthritis.
14. The method of claim 13 , wherein the sample is a blood or serum sample.
15. The method of claim 13 , wherein the mammalian subject is human.
16. The method of claim 13 , wherein the concentration of HMG1 is measured using an antibody that binds an HMG1 protein.
17. A prognostic method for monitoring the severity and predicting the likely clinical course of a mammalian subject having rheumatoid arthritis comprising measuring the concentration of HMG1 in a test sample from the subject, and comparing that concentration to a standard for HMG1 representative of a normal range of HMG1 in a Like sample, wherein the magnitude of the difference between the level of HMG1 in the test sample and the standard positively correlates with the severity of arthritis and with a poor prognosis of rheumatoid arthritis.
18. The method of claim 17 , wherein the sample is a blood or serum sample.
19. The method of claim 17 , wherein the mammalian subject is human.
20. The method of claim 17 , wherein the concentration of HMG1 is measured using an antibody that binds an HMG1 protein.
21. The method of claim 1 , wherein the condition is trauma hemorrhage.
22. The method of claim 7 , wherein the condition is trauma hemorrhage.
23. The method of claim 1 , wherein the condition is malaria.
24. The method of claim 7 , wherein the condition is malaria.